Browse studies

Find your next paid study

27,273 recruiting studies available now

Applied Physiology of Oxygen Toxicity: Mechanisms in Humans

The goal of this clinical trial is to learn about the mechanisms of oxygen toxicity in scuba divers. The main questions it aims to answer are: * How does the …

Oxygen ToxicityHypercapniaSeizures

Estimated

~$10 – $750

Actual pay is set by the research site.

Duke UniversityNCT05761756

Phase 3

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that …

Advanced Lung Non-Squamous Non-Small Cell CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaRecurrent Lung Non-Squamous Non-Small Cell Carcinoma+2 more

Estimated

~$50 – $1,350

Actual pay is set by the research site.

National Cancer Institute (NCI)

Observational

Navigation and Artificial Intelligence Technology for Indigenous Virtual Education on Smoking Cessation (NAITIVE)

This clinical trial develops a chatbot smartphone application (app), QuitBot, and text messaging to help American Indians (AI) and Alaska Natives (AN) to quit …

Cigarette Smoking-Related Carcinoma

Estimated

~$10 – $750

Actual pay is set by the research site.

Fred Hutchinson Cancer CenterNCT06697496

Phase 3

A Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy

The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with I…

Chronic Inflammatory Demyelinating Polyneuropathy

Estimated

~$50 – $2,250

Actual pay is set by the research site.

SanofiNCT06290141

Phase 2

A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease

This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated ki…

IgANC3GComplement-mediated Kidney Disease+2 more

Estimated

~$75 – $2,800

Actual pay is set by the research site.

ADARx Pharmaceuticals, Inc.NCT06989359

Phase 3

Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Nonfunctional Neuroendocrine Neoplasms (REMAIN Trial)

This is a multicenter, randomized, open-label, phase III study comparing standard of care use of somatostatin analogues (SSAs) to standard of care observation …

Neuroendocrine NeoplasmGastroenteropancreatic Neuroendocrine Neoplasm

Estimated

~$50 – $1,500

Actual pay is set by the research site.

Washington University School of MedicineNCT07842172

An Observational Study of Visual Attention, Object Recognition, and Eye Movements in Healthy Volunteers

Background: Vision is vital for many of our daily activities. Researchers want to learn more about how we aim our eyes (that is, what images, such as faces, i…

Healthy Volunteer

Estimated

~$10 – $675

Actual pay is set by the research site.

National Eye Institute (NEI)NCT07756853

Observational

Remote vs. In-Person Study Evaluation (RISE) Above Depression

The study will employ a randomized, parallel-group design with two-stage randomization. After an initial brief screen for basic eligibility, participants will …

Remote vs. In-PersonRemote VisitsIn-person Visits

Estimated

~$10 – $750

Actual pay is set by the research site.

State University of New York at BuffaloNCT07854301

Phase 1

A Phase 1/2 Study of the Menin Inhibitor Revumenib With the CELMod Mezigdomide in Relapsed/Refractory KMT2A-rearanged, NPM1-mutant, and NUP98-rearranged Acute Leukemias

The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-…

LeukemiaAcute LeukemiaRelapse Leukemia+5 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Memorial Sloan Kettering Cancer CenterNCT07356154

Phase 3

A Phase III, Multisite, Randomized, Double-Blind Trial of BNT327 in Combination With Chemotherapy Versus Placebo With Chemotherapy in Patients With Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC Determined Ineligible for PD(L)1 Therapy Based on PD-L1 Negative Disease

This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatme…

Breast Neoplasms

Estimated

~$50 – $2,250

Actual pay is set by the research site.

BioNTech SENCT07173751

Phase 3

A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Trial to Compare the Efficacy and Safety of a Fixed Dose of SEP-363856 to Placebo in the Treatment of Adults With Generalized Anxiety Disorder

This is a global, phase 3, randomized, double-blind, parallel-group, 2-arm, placebo controlled, multicenter trial designed to compare the efficacy, safety and …

Generalized Anxiety Disorder

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Otsuka Pharmaceutical Development & Commercialization, Inc.NCT07767903

Phase 1

Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms

Background: Alcohol use disorder (AUD) is a leading cause of disease and death worldwide. New treatments for AUD are needed. Dopamine, a chemical that carries…

Healthy VolunteersAlcohol Use Disorder (AUD)

Estimated

~$500 – $6,750

Actual pay is set by the research site.

National Institute on Alcohol Abuse and Alcoholism (NIAAA)NCT06484075